UroGen Pharma Ltd. (NASDAQ:URGN) Shares Purchased by Barclays PLC

Barclays PLC lifted its stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 409.3% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 59,778 shares of the company's stock after purchasing an additional 48,040 shares during the period. Barclays PLC owned about 0.25% of UroGen Pharma worth $759,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Point72 Asset Management L.P. increased its stake in UroGen Pharma by 120.3% during the 2nd quarter. Point72 Asset Management L.P. now owns 2,449,277 shares of the company's stock worth $41,099,000 after buying an additional 1,337,257 shares in the last quarter. Millennium Management LLC raised its stake in UroGen Pharma by 2,672.0% in the 2nd quarter. Millennium Management LLC now owns 1,160,899 shares of the company's stock valued at $19,480,000 after purchasing an additional 1,119,019 shares during the last quarter. Vestal Point Capital LP purchased a new position in UroGen Pharma in the 3rd quarter valued at $5,080,000. Great Point Partners LLC boosted its stake in UroGen Pharma by 10.9% during the 2nd quarter. Great Point Partners LLC now owns 2,906,259 shares of the company's stock worth $48,767,000 after purchasing an additional 285,714 shares during the last quarter. Finally, Stonepine Capital Management LLC purchased a new stake in shares of UroGen Pharma during the third quarter worth $3,560,000. Institutional investors and hedge funds own 91.29% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on URGN shares. D. Boral Capital restated a "buy" rating and set a $25.00 price target on shares of UroGen Pharma in a research report on Wednesday. Oppenheimer restated an "outperform" rating and set a $40.00 target price on shares of UroGen Pharma in a report on Wednesday, October 16th. HC Wainwright restated a "buy" rating and issued a $60.00 price target on shares of UroGen Pharma in a research report on Tuesday, October 15th. Finally, EF Hutton Acquisition Co. I upgraded UroGen Pharma to a "strong-buy" rating in a research report on Monday, October 14th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, UroGen Pharma currently has an average rating of "Buy" and an average price target of $43.70.

UroGen Pharma Trading Up 1.3 %

NASDAQ:URGN traded up $0.13 on Thursday, hitting $10.52. The stock had a trading volume of 314,056 shares, compared to its average volume of 484,703. The company has a fifty day moving average price of $11.50 and a two-hundred day moving average price of $13.21. The stock has a market cap of $246.74 million, a price-to-earnings ratio of -3.34 and a beta of 1.09. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. UroGen Pharma Ltd. has a 1-year low of $9.78 and a 1-year high of $20.70.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.55) EPS for the quarter, beating analysts' consensus estimates of ($0.84) by $0.29. The business had revenue of $25.20 million during the quarter, compared to analyst estimates of $24.22 million. During the same quarter in the prior year, the company posted ($0.68) earnings per share. Equities research analysts expect that UroGen Pharma Ltd. will post -3.1 earnings per share for the current fiscal year.

UroGen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.